Skip to Content



(lif i TEG rast)

Index Terms

  • Lifitegrast Sodium

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Ophthalmic:

Xiidra: 5% (5 ea)

Brand Names: U.S.

  • Xiidra

Pharmacologic Category

  • Lymphocyte Function-Associated Antigen 1 (LFA-1) Antagonist


Lifitegrast binds to the integrin lymphocyte function-associated antigen-1 (LFA-1) and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1).

Use: Labeled Indications

Dry eye disease: Treatment of the signs and symptoms of dry eye disease (DED).


There are no contraindications listed in the manufacturer's labeling.

Dosing: Adult

Dry eye disease: Ophthalmic: Instill 1 drop into each eye every 12 hours.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment

There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Hepatic Impairment

There are no dosage adjustments provided in the manufacturer’s labeling.


For topical ophthalmic use only. Remove contact lenses prior to administration and wait 15 minutes before reinserting. Do not touch the eye or surrounding area or any surface with the dropper tip to avoid contamination; discard single use container and unused solution after administration.


Store at 20°C to 25°C (68°F to 77°F). Store single-use containers in the original foil pouch.

Drug Interactions

There are no known significant interactions.

Adverse Reactions

5% to 25%:

Gastrointestinal: Dysgeusia

Local: Application site irritation

Ophthalmic: Decreased visual acuity

1% to 5%:

Central nervous system: Headache

Ophthalmic: Blurred vision, conjunctival hyperemia, eye discharge, eye discomfort, eye irritation, eye pruritus, increased lacrimation

Respiratory: Sinusitis


Special Populations:

• Contact lens wearers: Remove contact lens prior to administration and wait 15 minutes before reinserting.

Pregnancy Considerations

Adverse events were observed in some animal reproduction studies following intravenous administration. Systemic exposure following ophthalmic administration is low. In general, if ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctual occlusion to decrease potential exposure to the fetus (Samples 1988)

Patient Education

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Patient may experience eye irritation, change in taste, or blurred vision (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.